Athos Service: The Munich Family Office That Out-Patient'd Venture Capital
- Jörn Menninger
- 2 days ago
- 7 min read
Updated: 21 hours ago
Athos Service is the Munich-based operational arm of the Strüngmann family office (Santo Holding sits above it in Zug, with AT Impf and ATS Beteiligungsverwaltung as deal-specific SPVs). Its structural edge over venture capital: no LPs, no fund life, no exit timeline. That horizon let it anchor BioNTech for 11 years pre-revenue — turning €136.5M into a stake worth >$50 billion at peak (Aug 2021), still ~€10 billion today.
Every other quarter, a European policymaker calls for "more US-style venture capital" to fix the continent's deep-tech funding gap. Every time it happens, it's the wrong diagnosis.
Europe doesn't lack VC. Europe has a different and arguably better instrument for deep-tech bets: the operator-grade family office. The Strüngmanns' Athos Service is the canonical example. Its 17-year track record — culminating in the BioNTech anchor that turned €136.5M into $14B — outperforms any DACH venture fund on record. It does so because it's structurally different from a VC fund in every way that matters.
This piece is about *how* family-office capital out-patients venture capital, and why the discipline is harder to copy than it looks. It also notices a quiet convergence: the Strüngmann brothers and Susanne Klatten — Munich's two most consequential family-office anchors — both back the same ecosystem player (UnternehmerTUM). That isn't coincidence. It's the model in motion.
This is part 3 of the Strüngmann Cluster on Startuprad.io. Sits inside Power Structures: Hidden Champions and Ecosystem Gatekeepers.
Executive Summary
Family-office capital and venture capital look superficially similar — both write equity cheques into private companies. Structurally they're opposites. Family offices have no LPs, no fund-life clock, no exit obligation, and (when they're operator-led) deep domain expertise. For 10-15 year deep-tech bets, those differences are decisive. Athos Service has spent 21 years proving the point. Susanne Klatten's parallel commitments — also routed through Munich — show the model isn't a one-off.
Key Takeaways
No LPs = no clock. Athos doesn't have to exit at year 7 to return capital. It exited BioNTech in 2023 because the timing was right, not because the fund was closing.
Operator pedigree compounds. The Strüngmanns spent 19 years building Hexal. They evaluate a biotech pitch on the science, not on the team's pattern-match to Silicon Valley founders.
Discretion is itself a moat. Founders who want patient capital without media pressure self-select toward Athos. Public profile would dilute the moat.
The Klatten convergence is the proof. Susanne Klatten's family office and the Strüngmanns both back UnternehmerTUM (€25M / 10 years from the brothers; founding capital from Klatten in 2002). Munich's two anchor families are funding the same ecosystem player.
Replicating this is hard. It requires generational wealth that originated in operating expertise (not financial), willingness to forgo the leverage and reporting cycle of a fund structure, and editorial discipline about positioning.
The structural differences (and why they matter for biotech)
A venture fund is a partnership with a 7- to 10-year life. LPs commit capital to a vintage; the GP deploys it across 20-40 portfolio companies; the fund liquidates by year 10 (often via secondary sales, IPOs, or M&A). The economics are designed around this cycle — management fees, carry, the "2 and 20" model, distributions waterfalling back to LPs.
A single-family office isn't a partnership with anyone. It deploys family capital. It has no LPs to satisfy and no exit timeline to honour. If the right move is to hold a position for 12 years pre-revenue, it can. If the right move is to walk away in year 18 at peak valuation, it can do that too. The structure is permissionless.
For deep-tech bets — biotech, hard-tech, climate, advanced materials — the timeline mismatch with conventional VC is frequently lethal. BioNTech went 12 years (2008-2020) before COVID validated the platform commercially. A venture fund deploying into BioNTech in 2008 would have hit fund-life pressure around 2015-2018, exactly the moment when public-market exit options for an unproven platform company were minimal. Most US LPs would have pushed for a sale or a markdown by year 5-6.
Athos didn't face that pressure. It compounded.
Domain expertise as compounding asset
The second structural difference is who does the evaluation. A typical European VC fund has a pattern-matching layer: did this team go to the right schools, do they have the right pedigree, have they raised from the right co-investors. The mechanism is fundamentally Silicon Valley-imported.
The Strüngmanns spent 19 years building Hexal. They know what a generics development pipeline looks like. They know what scientific founder dynamics look like. When Şahin and Türeci pitched Ganymed in 2007, the brothers evaluated the science — not the founders' pattern-match to a US biotech archetype. The bet wasn't about whether Şahin had been to Stanford (he hadn't). It was about whether the mRNA platform was real (it was).
That domain expertise is hard to acquire and even harder to maintain across generations. It compounds in the brothers' specific case because they're still the operators — Athos isn't a discretionary fund managed by hired investment professionals. The brothers personally evaluate major bets. That's not scalable to a fund-of-funds structure or a sovereign wealth model.
The Klatten convergence
The clearest proof that the family-office model isn't a Strüngmann anomaly is Munich itself. Two anchor families — the Strüngmanns and the Quandt-Klatten branch — converge on the same ecosystem player.
Susanne Klatten founded UnternehmerTUM in 2002 — Europe's leading center for innovation and entrepreneurship, attached to the Technical University of Munich. UnternehmerTUM has produced 50+ high-growth startups per year for two decades, including Flix (FlixBus, $3B+ unicorn — interview with co-founder Jochen Engert), Celonis, Lilium, Isar Aerospace, Konux, e-bot7 (acquired by NASDAQ-listed LivePerson — original interview here, with the SEC-uncovered exit price covered separately), ProGlove (~€500M "Monster Exit"), and many others. Klatten serves on the TUM University Council. The funding came from the BMW heiress's family-office capital.
Two decades later, the Strüngmanns committed €25 million over 10 years to UnternehmerTUM and the TUM Venture Labs — the institutional layer Klatten built. The brothers also founded the Strüngmann Award (€100,000 for biotech entrepreneurs in DACH), a prize structure designed to surface the next generation of founders the family office might back later. Their broader ecosystem footprint includes the Ernst Strüngmann Institute (ESI) in Frankfurt — a neuroscience research center partnered with the Max Planck Society — and the Andreas & Susan Strüngmann Foundation, which funds South African educational and community programs (Andreas and his wife Susan maintain a second home there). The pattern is consistent: the brothers don't just back companies; they fund the institutional plumbing that produces the founders, the science, and the next generation of operators.
The portfolio outcomes are visible. Beyond BioNTech, founders coming through UnternehmerTUM-adjacent paths have produced exit-stage outcomes including Xaver Lehmann's e-bot7 sale to LivePerson (>$50M, SEC-confirmed), ProGlove's ~€500M "Monster Exit", and Flix's $3B+ mobility unicorn — all from the same Munich institutional layer that the two anchor families now jointly fund.
This convergence isn't coincidence. It's two operator-grade family offices recognising the same structural truth: the bottleneck in DACH biotech and deep-tech isn't capital — it's the founder pipeline that converts science into companies. So they fund the institution that converts that pipeline. Klatten built it. The Strüngmanns now reinforce it. The same Munich ecosystem layer compounds for both.
For a US venture investor, the equivalent move would be a16z and Sequoia jointly funding Y Combinator. It doesn't happen — partly because the cultural model doesn't recognise institutional plumbing as a venture-capital asset. In Munich it does.
What this means for non-DACH investors
If you're a US or UK fund looking at DACH biotech and wondering why the deals you can find aren't as compelling as the headline outcomes (BioNTech, Immatics, Tubulis), the structural reason is that the best deals are anchored by family offices before they reach venture syndicates. Athos can take the entire anchor position alone in early rounds — and frequently does. By the time a Series B or C opens to outside capital, the company has been de-risked and the anchor is locked.
That said, the brothers are not anti-institutional. On large transactions they regularly partner with EQT Private Equity — most notably the €2.15 billion 2014 acquisition of Siemens Audiology Solutions, which became WS Audiology, today a global hearing-aid leader. The pattern: family-office solo on early-stage and biotech-anchor positions; institutional co-investment when deal sizes exceed what makes sense for a single family office (€1B+) or when the brothers want operational expertise outside their core domain.
That's not a problem to solve. It's an architecture to understand. The DACH biotech ecosystem is structurally family-office-led. Working productively in it means co-existing with that architecture, not trying to replace it with a US-style venture playbook.
Tomorrow we close the cluster with Beyond BioNTech — what Athos is actually backing in 2026, and where the next decade goes.
FAQ
What is Athos Service? The Munich-based single-family office of Andreas and Thomas Strüngmann. Founded after the 2005 Hexal-Novartis exit. Biotech and life-sciences focused. Holds the BioNTech anchor (via AT Impf vehicle) plus positions in Immatics, Tubulis, Formycon, and recent investments in Antheia, AAVantgarde Bio, and Doctolib.
How is a family office different from venture capital? A venture fund has LPs, a fund life (typically 7-10 years), and an exit obligation. A single-family office has none of those. It deploys family capital with no time horizon, no LP reporting cycle, and no pressure to return capital on a schedule. For 10-15 year deep-tech bets, that horizon difference is structurally decisive.
Why did Athos work for BioNTech when VC wouldn't have? BioNTech went 12 years (2008-2020) pre-commercial-revenue. A venture fund deploying in 2008 would have hit fund-life pressure around 2015-2018, exactly when no exit options existed. Athos had no such pressure and compounded the position to a $14B peak in 2023.
What's the Strüngmann-Klatten connection? Both Munich-based family offices converge on UnternehmerTUM — Europe's leading center for innovation and entrepreneurship, attached to TU Munich. Susanne Klatten founded it in 2002 with family-office capital. The Strüngmanns committed €25M over 10 years in the 2020s to UnternehmerTUM and the TUM Venture Labs. Two anchor families, same ecosystem player.
Can the Athos model be replicated? With difficulty. It requires generational wealth that originated in operating expertise (not financial engineering), willingness to forgo the fund structure's leverage and reporting cycle, and the editorial discipline to stay private while operating at this scale. Most family offices that try it end up drifting into hedge-fund-style operations or private-bank discretionary management — both of which dilute the source of edge.
More on Startuprad.io
Read more in the Strüngmann Cluster: how the brothers built Germany’s most important biotech family office, the Hexal exit playbook, and what Athos is funding now in 2026. See also our Twin Billionaires hub and the Power Structures: Hidden Champions and Ecosystem Gatekeepers pillar.
About the Author
Joern "Joe" Menninger is the founder of Startuprad.io, Europe's leading English-language startup media platform covering the DACH region. With 740+ podcast episodes and over 1 million annual streams. Connect on LinkedIn